中国罕见病联盟执行理事长、全国罕见病诊疗协作网办公室副主任李林康介绍说：“随着医学的进步，我国血友病治疗效果和个体预防取得了很大进步。目前，血友病临床诊疗在药物选择、可及性及诊疗流程方面，相较其他罕见病有了长足进展。然而，中国血友病的整体治疗与国际相 ...

2024年10月11日，辉瑞宣布，美国食品药品监督管理局 (FDA) 已批准 Hympavzi（marstacimab）的上市申请，用于预防或减少患有 A 型血友病（先天性第 VIII ...

Marstacimab is the first anti-tissue factor pathway inhibitor (TFPI) antibody to secure FDA approval. “[Marstacimab] aims to reduce the current treatment burden by meeting an important need for ...

它通过靶向组织因子途径抑制剂（TFPI），可用于治疗血友病A和血友病B患者。 这款创新疗法获得美国FDA授予的快速通道资格。在2期临床试验中 ...

NO.5 辉瑞TFPI抗体Marstacimab在美获批 10月11日，辉瑞宣布TFPI抗体Marstacimab获得FDA批准上市，用于治疗A型和B型血友病。Marstacimab为组织因子途径抑制物 ...

HYMPAVZI, a rebalancing agent that targets the tissue factor pathway inhibitor’s (TFPI) Kunitz 2 domain, offers a once-weekly subcutaneous treatment option. TFPI is a natural anticoagulant ...

HYMPAVZI是美国首个且唯一获批用于治疗血友病A及血友病B的抗组织因子途径抑制剂（抗TFPI），也是美国首个通过预充自动注射笔给药的血友病创新 ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Novo’s anti-tissue factor pathway inhibitor (TFPI) antibody bagged a marketing recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP ...

Notably, the associations between MI and TNF-R2, TNF-R1, PGF, and TFPI went in opposite directions in the observational and ...

Marstacimab targets the Kunitz 2 domain of TFPI, offering a novel mechanism of action for hemophilia management. Pfizer now offers three classes of hemophilia treatments, enhancing therapeutic ...